GlassScriptPhysician profile
Ravikanth Vydyula
NPI 1942443551
$2,647.26
in general payments reported to CMS, 2019-2025
22 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $788 · 2021: $28.95 · 2023: $329 · 2024: $557 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.70 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $824.03 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $549.12 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Jazz Pharmaceuticals INC. | $185.19 | 2019-2025 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.23 | 2019-2024 | |
| Ethicon INC. | $125.72 | 2020 | |
| Ani Pharmaceuticals, INC. | $121.98 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $102.23 | 2023-2024 | |
| United Therapeutics Corporation | $102.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $61.94 | 2023-2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $58.27 | 2019-2020 | |
| Verona Pharma, INC. | $53.73 | 2025 | Ohtuvayre |
| Circassia INC. | $42.49 | 2019 | |
| Philips North America LLC | $41.32 | 2020-2023 | |
| Electromed, INC. | $37.41 | 2023-2024 | Smartvest |
| Pfizer INC. | $36.02 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $31.66 | 2020 | |
| Apria Healthcare LLC | $28.95 | 2021 | |
| Grifols USA, LLC | $24.31 | 2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $19.58 | 2019 | |
| Amgen INC. | $15.04 | 2024 | Tezspire |
| Inogen, INC. | $14.70 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mylan Specialty L.P. | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravikanth Vydyula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.